Ramaswamy Govindan, MD, Anheuser Busch Endowed Chair in Medical Oncology, Washington University School of Medicine in St. Louis, provides the condensed oral history of thoracic oncology – dating from the late 1990s to the present day. Chadi and Dr. Govindan discuss how stage III chemoradiation and PET scans were new strategies before the turn of the century, the introduction of gefitinib as a pivotal moment in the treatment paradigm, the doors opening for EGFR inhibitors, the discovery of ALK as a targetable mutation, how genome sequencing in the 2010s opened additional targets, PD-1 and PD-L1 inhibition, and so much more.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
